Status:
UNKNOWN
Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol
Lead Sponsor:
University of Campania Luigi Vanvitelli
Collaborating Sponsors:
IRCCS San Raffaele
Conditions:
Coronary Heart Disease
Angina
Eligibility:
All Genders
30-85 years
Phase:
PHASE4
Brief Summary
In hemodialysed patients, coronary heart disease is the leading cause of mortality and morbidity. Most of the commonly used drug for ischemia are used in this patients, but few prospective data are av...
Eligibility Criteria
Inclusion
- documented CAD evidenced by either coronary angiography (\>50% diameter stenosis of a major coronary artery) or a previously documented myocardial infarction
- transient ischemia evidenced by abnormalities during an exercise ECG (standard Bruce protocol), myocardial perfusion scintigraphy, or stress regional wall motion study done within 6 months of study entry
Exclusion
- unstable angina pectoris
- myocardial infarction or coronary revascularization within 3 months of study entry
- an ECG abnormality interfering with exercise ST-segment interpretation (eg, ST-segment depression \>0.5 mm, QRS duration \>0.1 second, R-wave amplitude \<8 mm,preexcitation,or atrial fibrillation)
- inability to undergo exercise testing
- uncontrolled hypertension
- other serious condition (medical, psychiatric, cognitive, or social)
- symptoms of sufficient severity (Canadian class II or higher) to require antianginal medications other than nitrates
- heart failure
- greater than first-degree atrio-ventricular block, asthma, or other contraindications to betablocker therapy
Key Trial Info
Start Date :
January 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2012
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT01425164
Start Date
January 1 2011
End Date
June 1 2012
Last Update
June 28 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chair of Cardiology Second University of Naples
Naples, Italy, 80100